Código QR (código de barras bidimensional)

Time and cost burden associated with docetaxel in patients with metastatic castration-sensitive prostate cancer initiating an androgen receptor pathway inhibitor-based regimen

BackgroundThe triplet combination of chemotherapy (docetaxel), androgen receptor pathway inhibitors (ARPI), and androgen deprivation therapy has recently become a recommended approach to treat metastatic castration-sensitive prostate cancer (mCSPC). This study aimed to compare the incremental time a...

ver descrição completa

Na minha lista:
Principais autores: Daniel Sentana-Lledo, Arjun Gupta, Carmine Rossi, Sabree Burbage, Jill Korsiak, Lilian Diaz, Gordon Wong, Dominic Pilon, Ibrahim Khilfeh, Alicia K. Morgans
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2025-09-01
coleção:Frontiers in Oncology
Assuntos:
androgen receptor antagonists
chemotherapy
hormone receptor agonists
mCSPC
prostate neoplasms
time burden
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fonc.2025.1650378/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados